Abstract:A pathological GGGGCC-hexanucleotide-repeat-expansion in the C9ORF72-gene has been described to underlie several neurodegenerative diseases. It has been found to be the most frequent genetic cause of sporadic and familial amyotrophic lateral sclerosis (ALS) and fronto-temporal dementia (FTD). Several pathogenic mechanisms have been suggested, including haploinsufficiency, abnormal sequestering of RNA-binding proteins by nuclear GGGGCC-repeat RNA-foci, and pathological dipeptiderepeat proteins derived from non–ATG-initiated translation from the expanded GGGGCC-repeat of the C9ORF72-gene. We report a 59-year-old German man with the rare co-occurrence of C9ORF72-ALS and systemic sarcoidosis. In January 2010, he presented initially with a 2-month history of myalgias and progressive muscle weakness affecting the distal legs. A brother died at age 59 due to bulbar ALS, and his mother, who suffered from progressive dementia, died at age 62. Key findings of his initial neurological work-up included atrophic paresis of distal legs, generalized fasciculations, attenuated ankle reflexes, slightly elevated serum creatine kinase levels, electromyographic evidence of acute and chronic denervation in tibialis anterior and gastrocnemius muscles, and prolonged central motor conduction times to the lower extremities. A familial ALS-FTD-syndrome was suspected. Because of rapid clinical deterioration and a diagnosis of cutaneous sarcoidosis in May 2010, he was reevaluated. In June 2010, a diagnosis of systemic sarcoidosis was made on the basis of mediastinal lymphadenopathy, bronchoalveolar lavage fluid lymphocytosis, and a diagnostic biopsy of the gastrocnemius muscle. In addition to typical sarcoid granulomata, the muscle biopsy showed mild neurogenic changes (Fig. 1A). Because a contribution of muscular or neuronal sarcoidosis to the development of atrophic muscle weakness could not be ruled out, immunosuppressive therapy was initiated, but it was stopped in February 2012 when a second biopsy showed marked neurogenic changes but no evidence of active sarcoidosis (Fig. 1B). At the same time, genetic analysis revealed a pathological hexanucleotide-repeat expansion of more than 600 repeats in C9ORF72. In July 2012, the patient died of respiratory failure. We investigated both muscle biopsies with regard to putative C9ORF72-, p62-, ubiquitin-, and TDP43-pathology. Immunoblot analysis of total muscle protein extracts from both biopsies showed a reduction of the long 54-kDa C9ORF72-isoform (Fig. 1E), which is in keeping with the hypothesis that C9ORF72-pathogenesis is due to haploinsufficiency. Indirect immunofluorescence analysis showed several muscle fibers with p62and ubiquitin-positive cytoplasmic aggregates (Fig. 1C,D), whereas TDP-43 staining did not show any overt pathology. These findings were also mirrored in immunoblots, which revealed increased levels of p62 and ubiquitinated proteins in both muscle biopsies compared with normal muscle controls and a case of muscle sarcoidosis with neurogenic changes (Fig. 1E). These findings indicate that the muscular cytoplasmic inclusions mirror the pathognomonic p62-positive, TDP43-negative neuronal cytoplasmic inclusions which have been found in the cerebral cortex, basal ganglia, hippocampus, and cerebellum of C9ORF72-ALS patients. With regard to the diagnosis and pathogenesis of the disorder, analysis of haploinsufficiency and protein aggregation pathology in skeletal muscle tissue from additional patients with pathological hexanucleotide-repeat-expansion of the C9ORF72-gene is warranted.

Discovery of a Missing Link: Detection and Structure of the Elusive Disilicon Carbide Cluster.

Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment

The effects of hyperthermia on polyribosomes and amino acid levels in infant rat brain

Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases

Abstract B33: Tumor-stromal response to immune checkpoint blockade within patient tissue derived three-dimensional lung tumor models

Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

Establishing A Patient-Derived Colorectal Cancer Xenograft Model For Translational Research

Patient-derived Human Tumour Tissue Xenografts in Immunodeficient Mice: a Systematic Review

Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models

Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes

In Silico Cancer Cell Versus Stroma Cellularity Index Computed from Species-Specific Human and Mouse Transcriptome of Xenograft Models: Towards Accurate Stroma Targeting Therapy Assessment

Cancer of the maxillary sinus

Abstract 5677: Establishment and application of a panel of PBMC-humanized mouse tumor models in immune-oncology and targeted cancer immunotherapy

Armillifer armillatus located within the lacrimal caruncle.

A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

Abstract 4703: Automated 42 PDX 3D in vitro tumor models of the TME screen immuno-oncology and targeted compounds and biologics for antitumor effects and MOA

Potential Perturbations of Critical Cancer-regulatory Genes in Triple-Negative Breast Cancer Cells Within the Humanized Microenvironment of Patient-derived Xenograft Models

Abstract 4250: Adherent and spheroid cell models of patient-derived xenograft for drug development and translational research

C9ORF72‐ALS: P62‐ and ubiquitin‐aggregation pathology in skeletal muscle

Progressive multifocal leukoencephalopathy in AIDS.

Progress in building clinically relevant patient‐derived tumor xenograft models for cancer research